Retension Pharmaceuticals Prices Upsized IPO at $12 per Share to Raise $45 Million
Retension Pharmaceuticals priced its upsized initial public offering at $12 per share, raising $45 million to fund its clinical pipeline.
IPOsBullish
IPOs
Every story explained in plain English, with the prices that matter beside it.
Retension Pharmaceuticals Prices Upsized IPO at $12 Per Share to Raise $45 Million
Retension Pharmaceuticals has priced its upsized initial public offering at $12.00 per share to fund clinical trials for its hypertension drug candidate.
TRex Bio Prices Initial Public Offering at $14 Per Share to Raise $116.7 Million
Immunology biotech TRex Bio has priced its market debut at $14 per share, raising $116.7 million to support its clinical pipeline as trading begins.
TRex Bio Prices Initial Public Offering at $14 Per Share to Raise $116.7 Million
Clinical-stage biotech firm TRex Bio priced its initial public offering to raise $116.7 million, with trading set to begin on the Nasdaq.
Jeff Bezos Suggests Blue Origin Could Go Public in Several Years
Jeff Bezos indicated rocket startup Blue Origin may go public, potentially separating his space ambitions from his holdings in Amazon.com, Inc.
Iambic Therapeutics Targets Over $800 Million Valuation In US IPO
AI drug discovery firm Iambic Therapeutics plans to raise up to $159 million in a Nasdaq IPO to advance its lead cancer treatment.
Blue Origin Eyes IPO in Coming Years Following 10 Billion Dollar Funding Round
Blue Origin plans a future IPO after raising 10 billion dollars in outside capital, marking a major shift in how Jeff Bezos funds its space expansion.
Leader’s Advantage Acquisition Corp. Completes $150 Million Initial Public Offering
Leader’s Advantage Acquisition Corp. raised $150 million in its initial public offering, placing over $151 million in a trust account.
Michael Burry Warns Anthropic Private Valuation Equals 78 S&P 500 Companies
Investor Michael Burry warned that Anthropic's private valuation could buy 78 S&P 500 firms, highlighting massive tech sector pricing discrepancies.
Research Firm Calls Anthropic IPO the Most Ridiculous of 2026
An independent research firm has labeled the planned Anthropic IPO as highly overvalued, citing massive net losses and competition from open-source AI.
Jeff Bezos Signals Blue Origin IPO Following 10 Billion Dollar Funding Round
Jeff Bezos says Blue Origin could go public in a few years following a new 10 billion dollar funding round that values the space firm at 140 billion dollars.
Spinal Implant Maker Centinel Spine Files for NYSE IPO Under Ticker CNTL
Centinel Spine has filed for an IPO on the NYSE. The spinal implant maker plans to use the proceeds to fund its growth and repay outstanding debt.
IPOsNeutral
Pine Tree Acquisition Corp. Closes $100 Million Initial Public Offering
Pine Tree Acquisition Corp. has finalized its $100 million initial public offering to fund future acquisition opportunities.
IPOsNeutral
FireFly Robotics Files for Nasdaq Direct Listing Under Ticker FFLY
FireFly Robotics has filed for a Nasdaq direct listing, offering existing shareholders liquidity without raising new capital.
IPOsNeutral
FireFly Robotics Files for Proposed Nasdaq Direct Listing Under Ticker FFLY
FireFly Robotics has filed a Form S-1 with the SEC for a proposed direct listing on Nasdaq, aiming to go public without raising new capital.
IPOsNeutral
FireFly Robotics Files for Nasdaq Direct Listing Under Ticker FFLY
Autonomous turf care manufacturer FireFly Robotics has filed for a Nasdaq direct listing as it looks to expand its robotic mowing and harvesting business.
IPOsMixed